1. Part 1 in the series. For additional data related to this work see: (a) Mjalli, A. M. M.; Sarshar, S. U.S. Patent 5,700,826, 1997; Chem. Abstr. 1998, 126, 8263. (b) Mjalli, A. M. M.; Sarshar, S. U.S. Patent 5,756,527, 1998; Chem. Abstr. 1998, 126, 352632. (c) Mjalli, A. M. M.; Zhang, C. U.S. Patent 5,840,721, 1998; Chem. Abstr. 1998, 126, 774230.
2. Bradley, G.; Naik, M.; Ling, V. Cancer Res. 1989, 49, 2790. For recent reviews see: (a) Ambukar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I.; Gottesman, M. M. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 361. (b) Ueda, K.; Yoshida, A.; Amachi, T. Anti-Cancer Drug Des. 1999, 14, 115. (c) Rappa, G.; Finch, R. A.; Sartorelli, A. C.; Lorico, A. Biochem. Pharmacol. 1999, 58, 557. (d) Robert, J. J. Eur. Clin. Inv. 1999, 29, 536.
3. P‐glycoprotein: multidrug‐resistance and a superfamily of membrane‐associated transport proteins
4. Clinical trials of agents that reverse multidrug resistance. A literature review